Lista de obras -

Arterial occlusive events in chronic myeloid leukemia patients treated with ponatinib in the real-life practice are predicted by the Systematic Coronary Risk Evaluation (SCORE) chart

scientific article published on 17 April 2019

Baseline factors associated with response to ruxolitinib: an independent study on 408 patients with myelofibrosis

artículo científico publicado en 2017

Cardiovascular toxicity in patients with chronic myeloid leukemia treated with second-generation tyrosine kinase inhibitors in the real-life practice: Identification of risk factors and the role of prophylaxis.

artículo científico publicado en 2018

Combination of EUTOS score and 3-month BCR-ABL transcript level identifies a group of good-risk chronic myeloid leukemia patients with favorable response to frontline imatinib therapy.

artículo científico publicado en 2015

Differences in presenting features, outcome and prognostic models in patients with primary myelofibrosis and post-polycythemia vera and/or post-essential thrombocythemia myelofibrosis treated with ruxolitinib. New perspective of the MYSEC-PM in a lar

artículo científico publicado en 2018

Digital PCR improves the quantitation of DMR and the selection of CML candidates to TKIs discontinuation

artículo científico publicado en 2019

Efficacy and safety of ruxolitinib in intermediate-1 IPSS risk myelofibrosis patients: Results from an independent study

artículo científico publicado en 2017

Epidemiology, outcome, and risk factors for infectious complications in myelofibrosis patients receiving ruxolitinib: A multicenter study on 446 patients.

artículo científico publicado en 2018

Favourable outcome of chronic myeloid leukemia co-expressing e13a2 and e14a2 transcripts, treated with nilotinib

scientific article published on 29 June 2020

Imatinib and polypharmacy in very old patients with chronic myeloid leukemia: effects on response rate, toxicity and outcome

artículo científico publicado en 2016

Impact of comorbidities and body mass index in patients with myelofibrosis treated with ruxolitinib

scientific article published on 04 December 2018

Life after ruxolitinib: Reasons for discontinuation, impact of disease phase, and outcomes in 218 patients with myelofibrosis

artículo científico publicado en 2019

Low low-density lipoprotein (LDL), cholesterol and triglycerides plasma levels are associated with reduced risk of arterial occlusive events in chronic myeloid leukemia patients treated with ponatinib in the real-life. A Campus CML study

artículo científico publicado en 2020

Ruxolitinib discontinuation syndrome: incidence, risk factors, and management in 251 patients with myelofibrosis

artículo científico publicado en 2021

Second cancer in Philadelphia negative myeloproliferative neoplasms (MPN-K). A nested case-control study

scientific article published on 29 May 2019

Second cancers in MPN: Survival analysis from an international study

artículo científico publicado en 2019

Second primary malignancy in myelofibrosis patients treated with ruxolitinib

artículo científico publicado en 2020

Lista de obras de

Arterial occlusive events in chronic myeloid leukemia patients treated with ponatinib in the real-life practice are predicted by the Systematic Coronary Risk Evaluation (SCORE) chart

Baseline factors associated with response to ruxolitinib: an independent study on 408 patients with myelofibrosis

Cardiovascular toxicity in patients with chronic myeloid leukemia treated with second-generation tyrosine kinase inhibitors in the real-life practice: Identification of risk factors and the role of prophylaxis.

Combination of EUTOS score and 3-month BCR-ABL transcript level identifies a group of good-risk chronic myeloid leukemia patients with favorable response to frontline imatinib therapy.

Differences in presenting features, outcome and prognostic models in patients with primary myelofibrosis and post-polycythemia vera and/or post-essential thrombocythemia myelofibrosis treated with ruxolitinib. New perspective of the MYSEC-PM in a lar

Digital PCR improves the quantitation of DMR and the selection of CML candidates to TKIs discontinuation

Efficacy and safety of ruxolitinib in intermediate-1 IPSS risk myelofibrosis patients: Results from an independent study

Epidemiology, outcome, and risk factors for infectious complications in myelofibrosis patients receiving ruxolitinib: A multicenter study on 446 patients.

Favourable outcome of chronic myeloid leukemia co-expressing e13a2 and e14a2 transcripts, treated with nilotinib

Imatinib and polypharmacy in very old patients with chronic myeloid leukemia: effects on response rate, toxicity and outcome

Impact of comorbidities and body mass index in patients with myelofibrosis treated with ruxolitinib

Life after ruxolitinib: Reasons for discontinuation, impact of disease phase, and outcomes in 218 patients with myelofibrosis

Low low-density lipoprotein (LDL), cholesterol and triglycerides plasma levels are associated with reduced risk of arterial occlusive events in chronic myeloid leukemia patients treated with ponatinib in the real-life. A Campus CML study

Ruxolitinib discontinuation syndrome: incidence, risk factors, and management in 251 patients with myelofibrosis

Second cancer in Philadelphia negative myeloproliferative neoplasms (MPN-K). A nested case-control study

Second cancers in MPN: Survival analysis from an international study

Second primary malignancy in myelofibrosis patients treated with ruxolitinib